glucuronate


Also found in: Dictionary, Encyclopedia, Wikipedia.

glucuronic acid

 [gloo″ku-ron´ik]
a uronic acid formed by oxidation of C-6 of glucose to a carboxy group; it occurs in proteoglycans (mucopolysaccharides), and is important in the conjugation of xenobiotics; it is conjugated to many poisons and drugs by the liver, forming glucuronides, which markedly decreases their toxicity and enhances their excretion by the liver, intestine, and kidney.

glu·cu·ro·nate

(glū-kū'rō-nāt),
A salt or ester of glucuronic acid.

glu·cu·ro·nate

(glū-kyūr'ō-nāt)
A salt or ester of glucuronic acid.
References in periodicals archive ?
The company has two compounds marketed in the United States: Hexalen(R) (altretamine) for the treatment of ovarian cancer, and NeuTrexin (trimetrexate glucuronate for injection) for the treatment of moderate- to-severe Pneumocystis carinii pneumonia, as well as a broad spectrum of drugs in various stages of development.
The company has two compounds marketed in the United States: Hexalen (altretamine) for the treatment of ovarian cancer, and NeuTrexin (trimetrexate glucuronate for injection) for the treatment of moderate-to-severe Pneumocystis carinii pneumonia, as well as a broad spectrum of drugs in various stages of development.
Trimetrexate is commercially available under the tradename NeuTrexin(TM) (trimetrexate glucuronate for injection) and distributed by US Bioscience (AMEX: UBS).
The company has two compounds marketed in the United States: Hexalen(R) (altretamine) for the treatment of ovarian cancer, and NeuTrexin(TM) (trimetrexate glucuronate for injection) for the treatment of moderate-to-severe Pneumocystis carinii pneumonia as well as a broad spectrum of drugs in various stages of development.
The company has two compounds marketed in the United States; Hexalen (altretamine) for the treatment of ovarian cancer and NeuTrexin (trimetrexate glucuronate for injection) for the treatment of moderate to severe Pneumocystis carinii pneumonia.
AMEX: UBS), reported today that the company has received clearance to market NeuTrexin(TM) (trimetrexate glucuronate for injection) in the United States.
Food and Drug Administration (FDA) has approved trimetrexate glucuronate for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP), a potentially fatal infection that often strikes people with AIDS.
The sales increase is attributable to both of the company's commercial products, Hexalen(R) (altretamine), a treatment for ovarian cancer, and NeuTrexin(TM) (trimetrexate glucuronate for injection), a product launched in January 1994 for the treatment of Pneumocystis carinii pneumonia.
The company has two compounds marketed in the United States; Hexalen(R) (altretamine) for the treatment of ovarian cancer, and NeuTrexin(TM) (trimetrexate glucuronate for injection) for the treatment of moderate-to-severe Pneumocystis carinii pneumonia, as well as a broad spectrum, of drugs in various stages of development.